Tag: Als treatment

Riluzole is the active ingredient in several FDA-approved medications for treating amyotrophic lateral sclerosis (ALS), which can sometimes lead to confusion about its different names. To address the question of **what is another name for riluzole?**, it is important to understand that the drug is sold under a few distinct brand names and forms, including tablets, a liquid suspension, and an oral film. These different formulations were developed to meet the varying needs of patients, especially those who experience swallowing difficulties as the disease progresses.

According to landmark clinical trials, Riluzole was associated with a statistically significant prolongation of survival for patients with Amyotrophic Lateral Sclerosis (ALS). This makes it the only widely available drug that prolongs survival in patients with ALS, a progressive neurodegenerative disease.

In the United States, approximately 2% of ALS cases are the genetic form known as SOD1-ALS [1.8.3]. For these patients, a targeted therapy approved in 2023 represents a major advancement. So, what is the newest drug for ALS, and how does it fit into the evolving landscape of treatment?

With a mean elimination half-life of 12 hours after repeated doses, the exact timeframe for how long does riluzole stay in your system depends on several physiological factors unique to each individual. This article explains the elimination process, how individual differences affect clearance, and what patients should know for safe medication management.

Approved by the FDA in 1995, riluzole was the first drug specifically developed for amyotrophic lateral sclerosis (ALS), with both clinical studies and real-world evidence confirming the significant benefits of taking riluzole tablets, particularly in prolonging patient survival. For those living with ALS, understanding these benefits is crucial for managing the disease's progression.